Combination of serum PSA assay, multi-parametric MRI and targeted prostate biopsy for prostate cancer screening in Nanjing

To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Zhonghua nan ke xue Ročník 25; číslo 9; s. 815
Hlavní autori: Liang, Jing, Zhao, Xiao-Zhi, Shi, Jing-Yan, Qiu, Xue-Feng, Zhang, Qing, Zhuang, Jun-Long, Wang, Wei, Deng, Yong-Ming, Huang, Hai-Feng, Zhang, Cheng-Wei, Guo, Hong-Qian
Médium: Journal Article
Jazyk:Chinese
Vydavateľské údaje: China 01.09.2019
Predmet:
Biopsy
China
Early Detection of Cancer - methods
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging
Male
Middle Aged
Prevalence
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
China
Nanjing area
multi-parametric MRI
MRI/ultrasound fusion biopsy
prostate cancer screening
prostate-specific antigen
ISSN:1009-3591
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community health service centers in Nanjing. We proposed multi-parametric MRI (mpMRI) for those with serum PSA ≥4 μg/L, transperineal systematic biopsy and MRI/ultrasound fusion targeted prostate biopsy for those who scored ≥3 points on the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2), transperineal systematic biopsy only for those with a PI-RADS v2 score of <3 and serum PSA ≥10 μg/L, and follow-up examinations every 6 months for those with a PI-RADS v2 score of <3 and serum PSA <4 μg/L. Among the 6 903 male subjects, 835 (12.1%) were found with serum PSA≥4 μg/L; 229 (77.4%) of the 296 men that received mpMRI scored ≥3 points on PI-RADS v2; and 79 (53.4%) of the 148 males that underwent prostate biopsy w
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1009-3591